Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.

Name: Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
License: Public Domain

GW Research Ltd

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

multiple-sclerosis

spasticity, multiple sclerosis, interventional, phase3

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.

Related documents